Follow-on Offering

Healthcare
Follow-on Offering

Summary

Baird served as a co-manager on this offering

About

Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ-GS:SRPT) recently completed a follow-on offering of 7.65 million common shares at a price of $42.50 per share, generating gross proceeds of approximately $325 million. In addition, Sarepta has granted the underwriters a 30-day option to purchase up to approximately 1.15 million additional shares of its common stock. The Company intends to use the net proceeds of this offering for the continuation and initiation of further clinical trials, commercialization, manufacturing, business development activities including the potential licensing or acquisition of complementary products and technologies and other general corporate purposes.

Sarepta is a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates. The Company is headquartered in Cambridge, Massachusetts.
CONTACT US TO LEARN MORE
Healthcare
Follow-on Offering
Date
July 2017
Company
Sarepta Therapeutics, Inc.
Transaction
M&A
Sectors
Healthcare
Target Location
North America
Acquiror Location
North America

Share